- Uterine Polyps Drugs play a critical role in the medical management of endometrial polyps, particularly in symptomatic women and those seeking fertility treatments. These drugs include hormonal therapies like Levonorgestrel, Progesterone, and Gonadotropin-Releasing Hormone (GnRH) agonists, which help in reducing polyp size and preventing recurrence
- The demand for these drugs is increasing due to the growing burden of uterine abnormalities, lifestyle changes, delayed childbearing, and higher diagnostic rates through techniques like transvaginal ultrasound and hysteroscopy
- North America is expected to dominate the Uterine Polyps Drug Market owing to advanced diagnostic infrastructure, high healthcare spending, and strong awareness about women’s reproductive health
- Asia-Pacific is projected to be the fastest-growing region during the forecast period, driven by increasing patient awareness, rising access to gynecological care, and improvements in healthcare infrastructure across emerging economies
- The Medication segment is expected to dominate the market with 64.5% of the share, propelled by a preference for non-invasive management before considering surgical options such as polypectomy or hysteroscopic removal.
